<- Go Home

Telomir Pharmaceuticals, Inc.

Telomir Pharmaceuticals, Inc., a preclinical stage pharmaceutical company, is engaged in the advancement of age reversal science. The company is developing Telomir 1, a small molecule intended to lengthen and protect telomeres, the DNA end caps of chromosomes that are associated with cellular aging. Telomir 1 is designed for oral administration and is aimed at extending longevity, improving quality of life, and potentially influencing biological aging. Telomir Pharmaceuticals is also involved in ongoing preclinical research into Progeria, diabetes, cancer, Alzheimer’s disease, osteoarthritis, and other age related conditions to assess the potential effects of Telomir 1. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida.

Market Cap

$154.0M

Volume

83.4K

Cash and Equivalents

$834.6K

EBITDA

N/A

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

N/A

Profit Margin

N/A

52 Week High

$20.72

52 Week Low

$3.11

Dividend

N/A

Price / Book Value

348.32

Price / Earnings

-6.54

Price / Tangible Book Value

348.32

Enterprise Value

$153.2M

Enterprise Value / EBITDA

N/A

Operating Income

-$10.4M

Return on Equity

1752.69%

Return on Assets

-204.69

Cash and Short Term Investments

$834.6K

Debt

$93.4K

Equity

$442.1K

Revenue

N/A

Unlevered FCF

-$1.7M

Sector

Pharmaceuticals

Category

N/A

Hedge Funds that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Yellowbrick Portfolios that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Company Stock Pitches